PMID- 9138660
OWN - NLM
STAT- MEDLINE
DCOM- 19970508
LR  - 20171116
IS  - 1055-9965 (Print)
IS  - 1055-9965 (Linking)
VI  - 6
IP  - 3
DP  - 1997 Mar
TI  - Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 
      5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal 
      women.
PG  - 177-81
AB  - Laboratory evidence suggests a role for dehydroepiandrosterone (DHEA) and its 
      metabolite 5-androstene-3 beta, 17 beta-diol (ADIOL) in mammary tumor growth. 
      Serum DHEA also has been related to breast cancer in postmenopausal women, but 
      the relationship of ADIOL to risk has not been evaluated previously. To assess 
      the relationship of serum DHEA, its sulfate (DHEAS), and ADIOL with breast cancer 
      risk in postmenopausal women, we conducted a prospective nested case-control 
      study using serum from the Columbia, MO Breast Cancer Serum Bank. Cases included 
      71 healthy postmenopausal volunteers not taking replacement estrogens when they 
      donated blood and who were diagnosed with breast cancer up to 10 years later 
      (median, 2.9 years). Two randomly selected controls, who also were postmenopausal 
      and not taking estrogens, were matched to each case on exact age, date (+/-1 
      year), and time (+/-2 h) of blood collection. Significant (trend P = 0.02) 
      gradients of increasing risk of breast cancer were observed for increasing 
      concentrations of DHEA and ADIOL, and women whose serum levels of these hormones 
      were in the highest quartiles were at a significantly elevated risk compared to 
      those in the lowest; their risk ratios were 4.0 [95% confidence interval (CI), 
      1.3-11.8) and 3.0 (95% CI, 1.0-8.6), respectively. The relationship of DHEAS to 
      breast cancer was less consistent, but women whose serum DHEAS concentration was 
      in the highest quartile also exhibited a significantly elevated risk ratio of 2.8 
      (95% CI, 1.1-7.4). Results of this prospective study support a role for the 
      adrenal androgens, DHEA, DHEAS, and ADIOL, in the etiology of breast cancer.
FAU - Dorgan, J F
AU  - Dorgan JF
AD  - Division of Cancer Prevention and Control, National Cancer Institute, NIH, 
      Bethesda, Maryland 20892-7326, USA.
FAU - Stanczyk, F Z
AU  - Stanczyk FZ
FAU - Longcope, C
AU  - Longcope C
FAU - Stephenson, H E Jr
AU  - Stephenson HE Jr
FAU - Chang, L
AU  - Chang L
FAU - Miller, R
AU  - Miller R
FAU - Franz, C
AU  - Franz C
FAU - Falk, R T
AU  - Falk RT
FAU - Kahle, L
AU  - Kahle L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American 
      Association for Cancer Research, cosponsored by the American Society of 
      Preventive Oncology
JID - 9200608
RN  - 0 (Anabolic Agents)
RN  - 459AG36T1B (Dehydroepiandrosterone)
RN  - 57B09Q7FJR (Dehydroepiandrosterone Sulfate)
RN  - 95PS51EMXY (Androstenediol)
SB  - IM
MH  - Aged
MH  - Anabolic Agents/*blood
MH  - Androstenediol/*blood
MH  - Bias
MH  - Blood Donors
MH  - Breast Neoplasms/*epidemiology
MH  - Case-Control Studies
MH  - Confidence Intervals
MH  - Dehydroepiandrosterone/*blood
MH  - Dehydroepiandrosterone Sulfate/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Linear Models
MH  - Middle Aged
MH  - Missouri/epidemiology
MH  - Odds Ratio
MH  - *Postmenopause/blood
MH  - Prospective Studies
MH  - Risk Factors
EDAT- 1997/03/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 1997 Mar;6(3):177-81.